You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 54 No. 3, March 1997 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL CONTRIBUTIONS
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

No Difference in Cerebral Glucose Metabolism in Patients With Alzheimer Disease and Differing Apolipoprotein E Genotypes

Elizabeth H. Corder, PhD; Vesna Jelic, MD; Hans Basun, MD, PhD; Lars Lannfelt, MD, PhD; Sven Valind, MD, PhD; Bengt Winblad, MD, PhD; Agneta Nordberg, MD, PhD

Arch Neurol. 1997;54(3):273-277.


Abstract

Background
Recent findings of a reduced cerebral metabolic rate of glucose (CMRGlu) in at-risk relatives of patients with Alzheimer disease (AD) who carry the apolipoprotein E (APOE) {epsilon}4 allele suggest a causative role for the E4 isoform in cognitive changes that lead to AD. It is not known whether {epsilon}4 allele—associated deficits exist in patients with clinical AD.

Objective
To determine whether distinct patterns of cerebral hypometabolism exist in patients who carry the {epsilon}4 allele.

Patients and Methods
Information on the CMRGlu and APOE genotype was available for 46 patients at a memory disorders clinic: 31 patients were diagnosed as having probable AD, 3 demented patients did not meet criteria for AD, and 12 patients had mild memory complaints. Positron emission tomography with the use of 18F-fludeoxyglucose was used to calculate the CMRGlu in the frontal and temporoparietal regions of the cortex. Estimates were standardized to the sensorimotor area of the cortex. Linear regression models were constructed to relate the APOE genotype to the CMRGlu, adjusting for cognitive status (ie, the Mini-Mental State Examination score).

Results
Distinct patterns of the CMRGlu did not emerge for patients with different APOE genotypes. Bilateral deficits in the CMRGlu were found in the patients with AD. Left-right asymmetry was found in 8 of 12 patients with mild memory complaints: 7 of 8 had CMRGlu ratios less than 0.85 in the left side of the temporoparietal region of the cortex.

Conclusions
The APOE {epsilon}4 allele does not appear to be associated with specific deficits in brain metabolism in patients with AD despite evidence that the {epsilon}4 allele is associated with preclinical alterations. This finding is consistent with previous epidemiologic results that have demonstrated a higher risk for AD in carriers of the {epsilon}4 allele, but no change in the rate of progression of AD.



Author Affiliations

From the Divisions of Geriatric Medicine (Drs Corder, Jelic, Basun, Lannfelt, Winblad, and Nordberg) and Nicotine Research (Dr Nordberg), Department of Clinical Neuroscience and Family Medicine, Karolinska Institute, Huddinge University Hospital, Huddinge, Sweden; the Center for Demographic Studies, Duke University, Durham, NC (Dr Corder); and the Uppsala University PET Centre, Uppsala, Sweden (Dr Valind).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Cerebral glucose metabolism in patients with AD and different APOE genotypes
Drzezga et al.
Neurology 2005;64:102-107.
ABSTRACT | FULL TEXT  

APOE-dependent PET patterns of brain activation in Alzheimer disease
Scarmeas et al.
Neurology 2004;63:913-915.
ABSTRACT | FULL TEXT  

Brain metabolic decreases related to the dose of the ApoE e4 allele in Alzheimer's disease
Mosconi et al.
J. Neurol. Neurosurg. Psychiatry 2004;75:370-376.
ABSTRACT | FULL TEXT  

Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia
Reiman et al.
Proc. Natl. Acad. Sci. USA 2004;101:284-289.
ABSTRACT | FULL TEXT  

Influence of the Apolipoprotein E Type 4 Allele on Cerebral Glucose Metabolism in Alzheimer's Disease Patients
Lee et al.
J. Neuropsychiatry Clin. Neurosi. 2003;15:78-83.
ABSTRACT | FULL TEXT  

The effect of APOE {epsilon}4 allele on cerebral glucose metabolism in AD is a function of age at onset
Hirono et al.
Neurology 2002;58:743-750.
ABSTRACT | FULL TEXT  

Apolipoprotein E {epsilon}4 and the pattern of regional brain atrophy in Alzheimer's disease
Hashimoto et al.
Neurology 2001;57:1461-1466.
ABSTRACT | FULL TEXT  

Declining brain activity in cognitively normal apolipoprotein E varepsilon 4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease
Reiman et al.
Proc. Natl. Acad. Sci. USA 2001;98:3334-3339.
ABSTRACT | FULL TEXT  

Single Photon Emission Computed Tomography and Apolipoprotein E in Alzheimer's Disease: Impact of the {varepsilon}4 Allele on Regional Cerebral Blood Flow
Hogh et al.
J Geriatr Psychiatry Neurol 2001;14:42-51.
ABSTRACT  

Lack of Effect of Apolipoprotein E E4 Allele on Neuropsychiatric Manifestations in Alzheimer's Disease
Hirono et al.
J. Neuropsychiatry Clin. Neurosi. 1999;11:66-70.
ABSTRACT | FULL TEXT  

Absence of an Apolipoprotein E {epsilon}4 Allele Is Associated With Increased Parietal Regional Cerebral Blood Flow Asymmetry in Alzheimer Disease
van Dyck et al.
Arch Neurol 1998;55:1460-1466.
ABSTRACT | FULL TEXT  

From the Cover: Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease
Small et al.
Proc. Natl. Acad. Sci. USA 2000;97:6037-6042.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1997 American Medical Association. All Rights Reserved.